Drugs Take Backseat to Seeds at Bayer With Monsanto AcquisitionBy
Health unit needs to do deals as top-seller faces competition
Bayer may lack cash, focus to keep scouting for new medicines
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.